Anti-Microtubule Drugs
- PMID: 27193863
- DOI: 10.1007/978-1-4939-3542-0_25
Anti-Microtubule Drugs
Abstract
Small molecule drugs that target microtubules (MTs), many of them natural products, have long been important tools in the MT field. Indeed, tubulin (Tb) was discovered, in part, as the protein binding partner of colchicine. Several anti-MT drug classes also have important medical uses, notably colchicine, which is used to treat gout, familial Mediterranean fever (FMF), and pericarditis, and the vinca alkaloids and taxanes, which are used to treat cancer. Anti-MT drugs have in common that they bind specifically to Tb in the dimer, MT or some other form. However, their effects on polymerization dynamics and on the human body differ markedly. Here we briefly review the most-studied molecules, and comment on their uses in basic research and medicine. Our focus is on practical applications of different anti-MT drugs in the laboratory, and key points that users should be aware of when designing experiments. We also touch on interesting unsolved problems, particularly in the area of medical applications. In our opinion, the mechanism by which any MT drug cures or treats any disease is still unsolved, despite decades of research. Solving this problem for particular drug-disease combinations might open new uses for old drugs, or provide insights into novel routes for treatment.
Keywords: Colchicine; Combretastatin A4; Microtubule drugs; Microtubules; Nocodazole; Paclitaxel; Vinblastine; Vincristine.
Similar articles
-
Microtubule-binding natural products for cancer therapy.Planta Med. 2010 Aug;76(11):1037-43. doi: 10.1055/s-0030-1250073. Epub 2010 Jun 24. Planta Med. 2010. PMID: 20577942 Review.
-
Microtubule dynamics as a target in oncology.Cancer Treat Rev. 2009 May;35(3):255-61. doi: 10.1016/j.ctrv.2008.11.001. Epub 2008 Dec 30. Cancer Treat Rev. 2009. PMID: 19117686 Free PMC article. Review.
-
Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.Eur J Med Chem. 2018 May 10;151:482-494. doi: 10.1016/j.ejmech.2018.04.011. Epub 2018 Apr 5. Eur J Med Chem. 2018. PMID: 29649743 Review.
-
Tubulins - the target for anticancer therapy.Curr Top Med Chem. 2015;15(1):73-82. doi: 10.2174/1568026615666150112115805. Curr Top Med Chem. 2015. PMID: 25579568 Review.
-
Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.PLoS One. 2017 Aug 7;12(8):e0182400. doi: 10.1371/journal.pone.0182400. eCollection 2017. PLoS One. 2017. PMID: 28787019 Free PMC article.
Cited by
-
Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect.J Enzyme Inhib Med Chem. 2021 Dec;36(1):802-818. doi: 10.1080/14756366.2021.1899168. J Enzyme Inhib Med Chem. 2021. PMID: 33730937 Free PMC article.
-
Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.PLoS Biol. 2018 Dec 20;16(12):e2006265. doi: 10.1371/journal.pbio.2006265. eCollection 2018 Dec. PLoS Biol. 2018. PMID: 30571694 Free PMC article.
-
Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.Cells. 2024 May 4;13(9):786. doi: 10.3390/cells13090786. Cells. 2024. PMID: 38727322 Free PMC article. Review.
-
Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.Front Oncol. 2022 Sep 15;12:907520. doi: 10.3389/fonc.2022.907520. eCollection 2022. Front Oncol. 2022. PMID: 36185294 Free PMC article. Review.
-
The small molecule AMBMP disrupts microtubule growth, ciliogenesis, cell polarity, and cell migration.Cytoskeleton (Hoboken). 2018 Oct;75(10):450-457. doi: 10.1002/cm.21496. Cytoskeleton (Hoboken). 2018. PMID: 30315640 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources